Amundi Asset Management US’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Amundi Asset Management US’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$2.6M	Buy	225,185 +2,009	+0.9%	+$23K	﹤0.01%	1151
2020 Q4	$2.15M	Buy	223,176 +16,309	+8%	+$156K	﹤0.01%	1122
2020 Q3	$1.86M	Buy	206,867 +59,928	+41%	+$634K	﹤0.01%	1107
2020 Q2	$1.81M	Buy	146,939 +37,726	+35%	+$427K	﹤0.01%	1095
2020 Q1	$981K	Sell	109,213 -18,126	-14%	-$186K	﹤0.01%	1100
2019 Q4	$1.25M	Buy	127,339 +26,028	+26%	+$232K	﹤0.01%	1205
2019 Q3	$697K	Sell	101,311 -4,400	-4%	-$33.7K	﹤0.01%	1280
2019 Q2	$976K	Buy	105,711 +3,950	+4%	+$47.6K	﹤0.01%	1257
2019 Q1	$1.6M	Buy	101,761 +9,571	+10%	+$169K	﹤0.01%	1135
2018 Q4	$1.42M	Buy	92,190 +18,324	+25%	+$376K	﹤0.01%	1100
2018 Q3	$1.59M	Buy	73,866 +1,369	+2%	+$31.8K	﹤0.01%	1179
2018 Q2	$1.76M	Buy	72,497 +1,297	+2%	+$26.4K	﹤0.01%	1147
2018 Q1	$1.22M	Buy	71,200 +12,158	+21%	+$237K	﹤0.01%	1157
2017 Q4	$1.12M	Buy	+59,042	New	+$888K	﹤0.01%	1189
2016 Q1	–	Sell	-354,962	Closed	-$23.3M	–	578
2015 Q4	$23.3M	Sell	354,962 -1,284,267	-78%	-$79.4M	0.09%	196
2015 Q3	$92.6M	Buy	1,639,229 +483,763	+42%	+$31.4M	0.38%	75
2015 Q2	$68.3M	Buy	1,155,466 +7,888	+0.7%	+$487K	0.25%	113
2015 Q1	$71.5M	Buy	1,147,578 +111,857	+11%	+$6.5M	0.26%	106
2014 Q4	$59.6M	Buy	1,035,721 +797,760	+335%	+$44.4M	0.22%	125
2014 Q3	$12.8M	Buy	237,961 +10,196	+4%	+$540K	0.05%	307
2014 Q2	$11.9M	Buy	227,765 +209,947	+1,178%	+$10.7M	0.05%	315
2014 Q1	$942K	Sell	17,818 -60,600	-77%	-$2.8M	﹤0.01%	581
2013 Q4	$3.14M	Sell	78,418 -772,960	-91%	-$30.4M	0.01%	501
2013 Q3	$32.2M	Buy	851,378 +88,907	+12%	+$3.47M	0.13%	186
2013 Q2	$29.9M	Buy	+762,471	New	+$29.7M	0.12%	200

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Amundi Asset Management US's TEVA Position: Q1 2021 in Review

Amundi Asset Management US increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 0.9% in Q1 2021, buying an estimated $23K and bringing the position to 225,185 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Amundi Asset Management US first reported a position in TEVA in Q2 2013 and has held it in 25 quarters since. The position peaked at $92.6M in Q3 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

Amundi Asset Management US held 225,185 shares of Teva Pharmaceutical Industries Limited worth $2.6M as of Q1 2021.
Amundi Asset Management US bought 2,009 Teva Pharmaceutical Industries Limited shares in Q1 2021, an estimated $23K.
Teva Pharmaceutical Industries Limited made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1151 holding.
Amundi Asset Management US first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and has held it in 25 quarters since.
Amundi Asset Management US's Teva Pharmaceutical Industries Limited position peaked at $92.6M in Q3 2015.
451 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.